Pamabrom
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326799

CAS#: 606-04-2

Description: Pamabrom is a diuretic product included in retail drugs available in over-the-counter medications. The active diuretic ingredient in pamabrom is 8-bromotheophylline. Pamabrom is used in combination with acetaminophen (paracetamol) for various conditions such as back pain and menstrual relief. The acetaminophen helps reduce menstrual pains and the pamabrom reduces associated bloating.


Price and Availability

Size
Price

1g
USD 150
10g
USD 850
Size
Price

2g
USD 250
20g
USD 1550
Size
Price

5g
USD 450
50g
Ask price

Pamabrom, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 326799
Name: Pamabrom
CAS#: 606-04-2
Chemical Formula: C11H18BrN5O3
Exact Mass:
Molecular Weight: 348.201
Elemental Analysis: C, 37.94; H, 5.21; Br, 22.95; N, 20.11; O, 13.78


Synonym: Pamabrom, trade name Diurex Max

IUPAC/Chemical Name: 8-bromo-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione compound with 2-amino-2-methylpropan-1-ol (1:1)

SMILES Code: CN(C(N1C)=O)C2=C(NC(Br)=N2)C1=O.CC(C)(N)CO


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Abdelaleem EA, Naguib IA, Hassan ES, Ali NW. HPTLC and RP-HPLC methods for simultaneous determination of Paracetamol and Pamabrom in presence of their potential impurities. J Pharm Biomed Anal. 2015 Oct 10;114:22-7. doi: 10.1016/j.jpba.2015.04.043. Epub 2015 May 8. PubMed PMID: 26001162.

2: Shah U, Kavad M, Raval M. Development and Validation of Stability-indicating RP-HPLC Method for Estimation of Pamabrom in Tablets. Indian J Pharm Sci. 2014 May;76(3):198-202. PubMed PMID: 25035530; PubMed Central PMCID: PMC4090826.

3: Tan DS, Sklar GE. Erythema multiforme secondary to dimenhydrinate in a patient with previous similar reactions to pamabrom. Ann Pharmacother. 2014 Mar;48(3):425-8. doi: 10.1177/1060028013518728. Epub 2014 Jan 6. PubMed PMID: 24396093.

4: El-Houssini OM. RP-LC and TLC Densitometric Determination of Paracetamol and Pamabrom in Presence of Hazardous Impurity of Paracetamol and Application to Pharmaceuticals. Anal Chem Insights. 2013 Sep 5;8:73-81. doi: 10.4137/ACI.S12349. eCollection 2013. PubMed PMID: 24046511; PubMed Central PMCID: PMC3771670.

5: Lee S, Yang Y, Fishman D, Banaszak Holl MM, Hong S. Epithelial-mesenchymal transition enhances nanoscale actin filament dynamics of ovarian cancer cells. J Phys Chem B. 2013 Aug 8;117(31):9233-40. doi: 10.1021/jp4055186. Epub 2013 Jul 26. PubMed PMID: 23848376; PubMed Central PMCID: PMC3784653.

6: Ortiz MI. Primary dysmenorrhea among Mexican university students: prevalence, impact and treatment. Eur J Obstet Gynecol Reprod Biol. 2010 Sep;152(1):73-7. doi: 10.1016/j.ejogrb.2010.04.015. Epub 2010 May 15. PubMed PMID: 20478651.

7: Ortiz MI, Rangel-Flores E, Carrillo-Alarcón LC, Veras-Godoy HA. Prevalence and impact of primary dysmenorrhea among Mexican high school students. Int J Gynaecol Obstet. 2009 Dec;107(3):240-3. doi: 10.1016/j.ijgo.2009.07.031. Epub 2009 Aug 27. PubMed PMID: 19716130.

8: Min JA, Kim HS, Kim HO, Park YM. Fixed drug eruption caused by pamabrom. Clin Exp Dermatol. 2009 Oct;34(7):e455-6. doi: 10.1111/j.1365-2230.2009.03501.x. Epub 2009 Aug 14. PubMed PMID: 19681920.

9: Ortiz MI, Fernández-Martínez E, Pérez-Hernández N, Macías A, Rangel-Flores E, Ponce-Monter H. Patterns of prescription and self-medication for treating primary dysmenorrhea in a Mexican population. Proc West Pharmacol Soc. 2007;50:165-7. PubMed PMID: 18605257.

10: Swanson JK, English JC 3rd. Serum sickness-like reaction to Pamabrom. J Drugs Dermatol. 2006 Mar;5(3):284-6. PubMed PMID: 16573265.

11: Di Girolamo G, Sánchez AJ, De Los Santos AR, González CD. Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea? Expert Opin Pharmacother. 2004 Mar;5(3):561-70. Review. PubMed PMID: 15013925.

12: Kauppinen K. Fixed drug eruptions and oral rechallenge. Cleve Clin J Med. 1991 Jan-Feb;58(1):64-5. PubMed PMID: 1829986.

13: Nedorost S, Taylor JS, Camisa C, Tomecki KJ, Helm T, Durkin WJ. Fixed drug eruption from pamabrom. Cleve Clin J Med. 1991 Jan-Feb;58(1):33-4. PubMed PMID: 1829985.

14: IANIUK VS. [The use of syncol in surgical practice]. Probl Gematol Pereliv Krovi. 1960 Aug;5:61-2. Russian. PubMed PMID: 13717260.

15: DOHERTY JE, BEARD OW. A study of diuretic action of pamabrom (2-amino-2-methyl-propanol-1-8-bromotheophylline) in cardiac failure. Am Heart J. 1953 Aug;46(2):288-90. PubMed PMID: 13080166.